Khondrion – in search of treatment for mitochondrial diseases

Khondrion – in search of treatment for mitochondrial diseases

11-10-2018

Interview with Jan Smeitink, CEO of Khondrion

Eight years ago, Jan Smeitink looked at himself in the mirror and decided he is going to change the world. Today, Jan is the Chief Executive Officer of Khondrion and is starting Phase 2b clinical trials for his revolutionary drug, KH176 – which might well become the first treatment on the market for people suffering from the devastating mitochondrial diseases.

We visited Jan, and his colleague Julien Beyrath, Chief Operating Officer, at the headquarters of Khondrion, a high-tech lab in a labyrinth of hallways at the Radboud Medical University in Nijmegen, the Netherlands.

Catalyze and Khondrion started working together more than 7 years ago and this was a celebratory visit, since Khondrion has recently been awarded a €2.3 Million SME Instrument Phase 2 grant. We took this opportunity to talk more about the inspiring mission of Khondrion and their journey.

Read complete interview

All services

In our approach we combine both non-dilutive and dilutive funding. Let’s start working on your project together now!

 

Welcome at Catalyze!

Catalyze uses cookies in order to improve your user experience. By using this website you agree to our policy.

Go back or